Abstract: Provided is a lithium (N-carbonyl)sulfonamide compound represented by the following Formula (I). In Formula (I), R1 and R2 each represent an alkyl group having from 1 to 10 carbon atoms, an alkenyl group having from 2 to 10 carbon atoms, an alkynyl group having from 2 to 10 carbon atoms, or an aryl group, and L1 and L2 each represent a single bond or —O—, with a proviso that a case in which L1 and L2 are both single bonds are excluded.

Abstract: Provided is a nonaqueous secondary battery including: a nonaqueous electrolyte solution that contains a compound (A) represented by the following Formula (I); a positive electrode that contains a positive electrode active material containing a compound (B) represented by the following Formula (II); and a negative electrode. The content of the compound (A) is more than 0% by mass but less than 1.0% by mass with respect to a total amount of the nonaqueous electrolyte solution. In Formula (I), X+ represents a hydrogen ion, a lithium ion, a sodium ion, or a potassium ion. In Formula (II), 0.1?a<1.3, 0.1<(1-b-c)<1.0, 0<b<0.6, and 0<c<0.6.

Abstract: The invention provides a CRISPR-dCas/Cas protein derivative or CRISPR-dCas/Cas protein derivative set derived from a CRISPR-dCas (dead Cas) protein or a CRISPR-Cas protein, as well as a polynucleotide encoding the same, a vector comprising the polynucleotide, a transformant transformed by the vector, a carrier for purifying a target RNA, a method for purifying a target RNA, a method for analyzing an intracellular environment, and a prophylactic or therapeutic agent.

Abstract: The present invention provides a nucleic acid construct containing at least one guide RNA portion that binds to one or more target RNAs and an RNA-cleaving Cas protein expression portion, wherein the one or more target RNAs are derived from a mutation in a vertebrate cell, a virus, or a bacterium.